Periprosthetic infections following total hip replacement with ESBL-forming bacteria : Importance for clinical practice;Periprothetische Infektionen nach Hüfttotalendoprothese mit ESBL-bildenden Bakterien : Bedeutung für die klinische Praxis

Orthopade

Volumn 40, Issue 6, 2011, Pages 528-534

  Haenle, M ^a   Podbielski, A ^a   Ellenrieder, M ^a   Skripitz, R ^a   Arndt, K ^a   Mittelmeier, W ^a   Bader, R ^a   Gollwitzer, H ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Extended spectrum lactamase (ESBL); Multiresistant; Periprosthetic infection; Revision surgery; Total hip replacement

Indexed keywords

BETA LACTAMASE;

ARTICLE; BIOSYNTHESIS; ENTEROBACTERIACEAE INFECTION; HIP ARTHROPLASTY; HIP PROSTHESIS; HUMAN; METABOLISM;

ARTHROPLASTY, REPLACEMENT, HIP; BETA-LACTAMASES; ENTEROBACTERIACEAE INFECTIONS; HIP PROSTHESIS; HUMANS;

EID: 79958701402     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00132-011-1762-1     Document Type: Article

References (31)

1. Malchau H, Herberts P, Eisler T et al (2002) The Swedish Total Hip Replacement Register. J Bone Joint Surg [Am] 84-A(suppl 2):2-20
2. Geipel U, Hermann M (2004) Das infizierte Implantat. Teil 1: Bakteriologie. Orthopade 33:1411-1428
3. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18(4):657-686
4. Witte W, Mielke M (2003) β-Laktamasen mit breitem Wirkungsspektrum. Grundlagen, Epidemiologie, Schlussfolgerungen für die Prävention. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 46:881-890
5. Jarlier V, Nicolas MH, Fournier G, Philippon A (1988) Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10(4):867-878
6. Ambler RP, Meadway RJ (1969) Chemical structure of bacterial penicillinases. Nature 222(5188):24-26
7. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39(6):1211-1233
8. Jacoby GA (1994) Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13(suppl 1):S2-S11
9. Livermore DM (2008) Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 14(suppl 1):3-10
10. Giske CG, Sundsfjord AS, Kahlmeter G et al (2009) Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother 63(1):1-4
11. Jacoby GA, Munoz-Price LS (2005) The new beta-lactamases. N Engl J Med 352(4):380-391
12. Paterson DL, Rossi F, Baquero F et al (2005) In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55(6):965-973
13. Coque TM, Baquero F, Canton R (2008) Increasing prevalence of ESBL-producing enterobacteriaceae in Europe. Euro Surveill 13(47), pii: 19044
14. Bradford PA, Urban C, Jaiswal A et al (1995) SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 39(4):899-905
15. Siegel JD, Rhinehart E, Jackson M, Chiarello L (2007) 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 35(10 suppl 2):S65-S164
16. Reddy P, Malczynski M, Obias A et al (2007) Screening for extended-spectrum beta-lactamase-producing enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 45(7):846-852
17. Garvin KL, Hinrichs SH, Urban JA (1999) Emerging antibiotic-resistant bacteria. Their treatment in total joint arthroplasty. Clin Orthop Relat Res 369:110-123
18. Haenle M, Podbielski A, Mittelmeier W et al (2010) Infections after primary and revision total hip replacement caused by enterobacteria producing extended spectrum beta-lactamases (ESBL): a case series. Hip Int 20(2):248-254
19. Martinez-Pastor JC, Vilchez F, Pitart C et al (2010) Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae. Eur J Clin Microbiol Infect Dis 29(8):1039-1041
20. Ribes J, Rapp RP (2005) Why is the microbiology lab calling about an extended-spectrum beta-lactamase bacterium from a wound culture? Orthopedics 28(11):1322-1325
21. Standards NCfCL (2005) Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15). National Committee for Clinical Laboratory Standards, Wayne, PA
22. Pfaller MA, Segreti J (2006) Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 42(suppl 4):S153-S163
23. Rupp ME, Fey PD (2003) Extended spectrum beta-lactamase (ESBL)-producinge Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63(4):353-365
24. Siegel JD, Rhinehart E, Jackson M, Chiarello L (2007) Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 35(10 suppl 2):S165-S193
25. Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8(3):159-166
26. Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56(1): 52-59
27. Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351(16): 1645-1654
28. Lohmann CH, Furst M, Niggemeyer O, Ruther W (2007) The treatment of periprosthetic infections. Z Rheumatol 66(1):28-33
29. Frommelt L (2004) Guidelines on antimicrobial therapy in situations of periprosthetic THR infection. Orthopade 33(7):822-828
30. Persson C, Baleani M, Guandalini L et al (2006) Mechanical effects of the use of vancomycin and meropenem in acrylic bone cement. Acta Orthop 77(4):617-621
31. Baleani M, Persson C, Zolezzi C et al (2008) Biological and biomechanical effects of vancomycin and meropenem in acrylic bone cement. J Arthroplasty 23(8):1232-1238